DIABETES
Diabetes is a pandemic that is accelerating at an alarming rate. Today, more than 380 million people, across all age groups and social classes live with the disease globally. What is even more worrying is the fact that this condition mostly goes undetected until it reaches life-threatening proportions.
The constant monitoring apart from the actual treatment makes diabetes management an expensive process. As a credible, global insulins player, Biocon is committed to making insulin-based therapy increasingly affordable and accessible across the globe.
Biocon’s Insugen®- Effective and affordable
Biocon’s Glargine, Basalog®
The first biosimilar from India to be approved in Japan
Sincerely Pharmaceutical Tech
Regards,
Client Success Team (CRM),
Please fill the all required fields....!!
Sincerely Packaging Labelling